Impact of Spanish government's COVID-19 measures on life sciences companies operating in Spain

Published date20 March 2020
Subject MatterLife Sciences,Healthcare Facilities,Supply Chain,Ministry of Health,Emergency Management Plans,Spain,Public Health,Pharmaceutical Industry,Coronavirus/COVID-19
AuthorSantiago Garrido de las Heras,Álvaro Abad,Alex Dolmans,Adrián Fernández de Pedro
Law FirmHogan Lovells

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT